Journal
CURRENT OPINION IN GENETICS & DEVELOPMENT
Volume 20, Issue 1, Pages 87-90Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.gde.2009.11.002
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA140594-01, P01 CA089021, R01 CA140594, R01 CA137008, K08 CA120060-04, R01 CA122794, R01 CA137008-01, R01 CA122794-04, P01 CA089021-05, K08 CA120060] Funding Source: Medline
- NIGMS NIH HHS [R01 GM036624, R01 GM056203, R01 GM041890, R01 GM056203-13, R01 GM036624-22] Funding Source: Medline
Ask authors/readers for more resources
The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
